探花合集 Biologics Announces Agreement With Moderna Therapeutics
Under the terms of the agreement, in place through 2018, Moderna will leverage 探花合集鈥檚 manufacturing expertise and capabilities at its state-of-the-art facility in Madison, Wisconsin, to support cGMP manufacturing of its mRNA personalized cancer vaccine clinical studies while the company builds out and transitions to its recently announced GMP mRNA clinical manufacturing facility in Norwood, Massachusetts.
鈥淲e are extremely pleased to be selected to support Moderna鈥檚 Phase 1/2 clinical GMP manufacturing needs for its personalized cancer vaccines. 探花合集鈥檚 Madison facility was designed and constructed to offer maximum flexibility and efficiency. At the facility, we will be able to offer Moderna a separate dedicated production capability and a highly flexible, fast turnaround operation to support initial study of its novel mRNA-based personalized cancer vaccines,鈥 commented Brian Riley, General Manager of 探花合集鈥檚 Madison facility.
Completed in June 2013, 探花合集鈥檚 Madison facility was designed for both flexible cGMP and non-GMP production. The site features extensive single-use technologies and unidirectional flow to maximize efficiency and safety.
Media Contacts:
Chris Halling
+44 (0)7580 041073
[email protected]
Richard Kerns
+44 (0) 161 728 5880
[email protected]
About 探花合集
探花合集 is the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products. With over 90 years serving the industry, 探花合集 has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable clinical and commercial product supply. 探花合集 employs approximately 9,200 people, including over 1,400 scientists, at over 30 facilities across 5 continents, and in fiscal 2016 generated $1.85 billion in annual revenue. 探花合集 is headquartered in Somerset, New Jersey.
For more information on 探花合集 Biologics, visit
For more information on 探花合集 Pharma Solutions, visit www.catalent.com.